Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Net Income (2017 - 2025)

Historic Net Income for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to -$15.3 million.

  • Aclaris Therapeutics' Net Income fell 8077.83% to -$15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$145.2 million, marking a year-over-year decrease of 27948.52%. This contributed to the annual value of -$132.1 million for FY2024, which is 4925.8% down from last year.
  • Latest data reveals that Aclaris Therapeutics reported Net Income of -$15.3 million as of Q3 2025, which was down 8077.83% from -$16.4 million recorded in Q2 2025.
  • Aclaris Therapeutics' 5-year Net Income high stood at -$1.9 million for Q4 2023, and its period low was -$97.6 million during Q4 2024.
  • Over the past 5 years, Aclaris Therapeutics' median Net Income value was -$20.3 million (recorded in 2021), while the average stood at -$23.9 million.
  • Its Net Income has fluctuated over the past 5 years, first plummeted by 6658888.89% in 2021, then skyrocketed by 9361.05% in 2023.
  • Quarter analysis of 5 years shows Aclaris Therapeutics' Net Income stood at -$22.9 million in 2021, then fell by 27.02% to -$29.1 million in 2022, then skyrocketed by 93.61% to -$1.9 million in 2023, then tumbled by 5151.45% to -$97.6 million in 2024, then surged by 84.29% to -$15.3 million in 2025.
  • Its Net Income was -$15.3 million in Q3 2025, compared to -$16.4 million in Q2 2025 and -$15.9 million in Q1 2025.